Bedrijfsoverzicht
Teva Pharmaceutical Industries Limited is a major global entity focused on the development, manufacturing, marketing, and distribution of generic and other medicines, as well as biopharmaceutical products across the United States, Europe, Israel, and international markets. The company operates within the Healthcare sector, specifically categorized under the Drug Manufacturers - Specialty & Generic industry, which positions it as a key supplier of essential pharmaceuticals rather than a primary innovator of novel drug compounds. In terms of scale, Teva boasts a substantial market capitalization of $36.77B and generates annual revenue (TTM) of $17.26B while employing a workforce of 31,173 individuals. These valuation and revenue figures indicate that Teva maintains a significant footprint in the global pharmaceutical supply chain, serving as a critical source of accessible medication for millions of patients worldwide.
Financiële gezondheid
The company reported a revenue of $17.26B and net income of $1.41B over the trailing twelve months, supported by an EBITDA of $4.95B. The substantial gap between the $17.26B revenue and the $1.41B net income reveals a cost structure where approximately 91.8% of revenue is consumed by costs of goods sold, operating expenses, and taxes before arriving at the bottom line. Teva generates free cash flow of $2.03B, which provides the organization with significant financial flexibility to fund operations, service debt obligations, or pursue strategic acquisitions without immediate reliance on external financing. Profitability is analyzed through three key margins: a gross margin of 51.8%, an operating margin of 27.3%, and a profit margin of 8.2%. The gross margin of 51.8% reflects the pricing power and manufacturing efficiency in producing generic medicines, while the operating margin of 27.3% indicates effective control over overhead costs, and the profit margin of 8.2% demonstrates the final return after all corporate expenses and taxes are deducted. Regarding liquidity and leverage, the company holds $3.56B in cash against $17.23B in total debt, resulting in a debt-to-equity ratio of 217.72 which suggests a highly leveraged balance sheet typical for capital-intensive pharmaceutical manufacturing. The current ratio stands at 1.04, indicating that the company's current assets are only slightly higher than its current liabilities, suggesting a tight but manageable short-term liquidity position. Return metrics show a Return on Equity of 20.8% and a Return on Assets of 6.2%, revealing that management is highly effective at generating returns for shareholders relative to the equity invested, though the lower ROA reflects the impact of the significant asset base and high debt load.
Waarderingsbeoordeling
Valuation metrics present a mix of historical profitability and future expectations, highlighted by a P/E Ratio (TTM) of 25.47 compared to a Forward P/E of 9.90. The significant difference between the trailing P/E of 25.47 and the forward P/E of 9.90 implies that the market expects earnings to grow substantially in the coming year, potentially driven by the resolution of generic patent cliffs or successful new product launches. The price-to-book ratio is 4.48, indicating that the stock trades at a substantial premium of over four times its book value, reflecting intangible assets such as patents and brand equity that are not fully captured on the balance sheet. Alternative valuation metrics include a price-to-sales ratio of 2.13 and an EV/EBITDA of 9.91, which suggest the company is valued at roughly two times its sales revenue and nearly ten times its operating earnings, placing it in a moderate valuation band relative to the broader pharmaceutical sector. Price volatility is contextualized by a 52-week high of $37.35 and a 52-week low of $13.04, illustrating a wide trading range where the stock has experienced significant price discovery over the last year. The beta value of 0.76 indicates that the stock is less volatile than the broader market, moving with less intensity than the overall index during periods of market stress or rally.
Growth & Income
Revenue growth is reported at 11.4% year-over-year, while earnings growth is listed as N/A, suggesting that current earnings data may not be available for a comparable prior period or is not disclosed in the provided metrics. The absence of a specific earnings growth percentage makes it difficult to directly compare earnings expansion to revenue expansion, but the robust 11.4% revenue growth indicates strong top-line expansion in the generic pharmaceutical market. Teva does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning the company chooses to reinvest all available earnings into business growth, R&D, and capacity expansion rather than distributing cash to shareholders. This capital allocation strategy prioritizes long-term market share gains and product portfolio development over immediate income generation for investors seeking passive dividend income. Overall, the company presents a growth-oriented profile with strong revenue expansion and zero dividend distribution, relying on share price appreciation and operational efficiency to deliver value to its equity holders.